Ching-Tung Chen

发表

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Enzo Medico, Roberta Schiavo, F. Nicolantonio, 2012, Nature.

MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells

J. Christensen, M. Weiser, S. Gao, 2012, Molecular Cancer Therapeutics.

Programme of self-reactive innate-like T cell-mediated cancer immunity

C. Leslie, M. Weiser, Ming O. Li, 2022, Nature.

A rectal cancer model establishes a platform to study individual responses to chemoradiation

Hans Clevers, Lukas E. Dow, Jinru Shia, 2019, bioRxiv.

A rectal cancer organoid platform to study individual responses to chemoradiation

Jessica A Lavery, Iva Petkovska, Harini Veeraraghavan, 2019, Nature Medicine.

An immunocompetent rectal cancer model to study radiation therapy

S. Lowe, C. Sawyers, Seo-Hyun Choi, 2022, bioRxiv.

Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer

M. Gonen, J. Guillem, G. Nash, 2022, The oncologist.

Single Nucleotide Polymorphism TGFβ1 R25P Correlates with Acute Toxicity during Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients.

K. Goodman, Ching-Tung Chen, J. Garcia-Aguilar, 2017, International journal of radiation oncology, biology, physics.

KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy

M. Berger, M. Weiser, N. Camacho, 2016, Annals of Surgical Oncology.

Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer

N. Schultz, M. Berger, D. Solit, 2022, Nature Medicine.

Detection of methylated BCAT1 and IKZF1 in stage II/III rectal cancer receiving chemoradiation.

M. Weiser, Ching-Tung Chen, P. Aggarwal, 2019, Journal of Clinical Oncology.

Preclinical Development MET Activation Mediates Resistance to Lapatinib Inhibition of HER 2-Ampli fi ed Gastric Cancer Cells

J. Christensen, M. Weiser, S. Gao, 2012 .

L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition

Narasimhan P. Agaram, C. Antonescu, M. Weiser, 2007, International journal of cancer.

c-MET and HGF mRNA expression in hepatocellular carcinoma: correlation with clinicopathological features and survival.

M. D'Angelica, W. Jarnagin, G. Abou-Alfa, 2013, Anticancer research.

c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases.

F. Barany, G. Nash, M. Weiser, 2008, Cancer letters.

HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells

N. Rosen, D. Solit, J. Christensen, 2008, Molecular Cancer Therapeutics.

KRAS mutant rectal cancer cells interact with surrounding fibroblasts to deplete the extracellular matrix

C. Leslie, S. Lowe, K. Manova-Todorova, 2021, Molecular oncology.

HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation

J. Christensen, M. Weiser, D. Líška, 2009, Clinical Cancer Research.

Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: updated results.

D. Lake, C. Hudis, L. Norton, 2009 .

Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant POLE/POLD1 Colon Cancer

M. Gonen, M. Weiser, Z. Stadler, 2021, JCO precision oncology.

Antitumor Activity of SNX-2112, a Synthetic Heat Shock Protein-90 Inhibitor, in MET-Amplified Tumor Cells with or without Resistance to Selective MET Inhibition

A. Olshen, A. Viale, N. Rosen, 2011, Clinical Cancer Research.

Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma efficiently.

Y. Fong, Yong A. Yu, A. Szalay, 2014, Surgery.

Integrated genomic profiling identifies microRNA‐92a regulation of IQGAP2 in locally advanced rectal cancer

C. Leslie, M. Setty, Raphael A. Pelossof, 2016, Genes, chromosomes & cancer.

KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer.

F. Sánchez-Vega, Raphael A. Pelossof, Seo-Hyun Choi, 2022, Molecular cancer research : MCR.

Identifying Diagnostic MicroRNAs and Investigating Their Biological Implications in Rectal Cancer

F. Sánchez-Vega, Ching-Tung Chen, J. Garcia-Aguilar, 2021, JAMA network open.

Novel xenograft model expressing human hepatocyte growth factor shows ligand-dependent growth of c-Met–expressing tumors

M. Weiser, Z. Zeng, R. DeMatteo, 2007, Molecular Cancer Therapeutics.

Do differences in the microbiome explain early onset in colon cancer?

M. Gonen, M. Weiser, A. Zehir, 2020 .

A KRAS mutation is associated with an immunosuppressive tumor microenvironment in mismatch-repair proficient colorectal cancer.

Raphael A. Pelossof, Seo-Hyun Choi, Ching-Tung Chen, 2019, Journal of Clinical Oncology.

Characteristics of Mismatch Repair–Deficient Colon Cancer in Relation to Mismatch Repair Protein Loss, Hypermethylation Silencing, and Constitutional and Biallelic Somatic Mismatch Repair Gene Pathogenic Variants

M. Gonen, M. Weiser, Z. Stadler, 2022, Diseases of the colon and rectum.

Antitumor activity of SNX-2112, a synthetic heat shock protein 90 inhibitor, in malignancies with amplification of the MET oncogene.

A. Olshen, A. Viale, N. Rosen, 2010 .

Abstract 6095: Unique tumor microbiome in microsatellite instability high (MSI-H) colon carcinoma

M. Ladanyi, M. Berger, M. Weiser, 2020 .

Antitumor Activity of SNX-2112, a Synthetic Heat Shock Protein-90 Inhibitor, in MET-Amplified Tumor Cells with or without Resistance to Selective MET Inhibition

A. Olshen, A. Viale, N. Rosen, 2011, Clinical Cancer Research.

P2.08 Emergence of Kras Mutations and Acquired Resistance to Anti Egfr Therapy in Colorectal Cancer

F. Nicolantonio, A. Bardelli, M. Janakiraman, 2012 .

Intratumoral T-cell repertoires in DNA mismatch repair-proficient and -deficient colon tumors containing high or low numbers of tumor-infiltrating lymphocytes

M. Weiser, Z. Stadler, N. Segal, 2022, Oncoimmunology.

An immunocompetent rectal cancer model to study radiation therapy

S. Lowe, C. Sawyers, Seo-Hyun Choi, 2022, Cell Reports Methods.